Advertisement

Japanese Journal of Ophthalmology

, Volume 63, Issue 1, pp 100–108 | Cite as

The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy

  • Shunichiro Nakai
  • Wataru Matsumiya
  • Otsuka Keiko
  • Akiko Miki
  • Makoto Nakamura
  • Shigeru Honda
Clinical Investigation
  • 117 Downloads

Abstract

Purpose

This study was prospectively carried out to clarify the effectiveness of visual and anatomical outcomes under combination therapy of intravitreal aflibercept (IVA) and verteporfin photodynamic therapy (vPDT) in over 24 months.

Study design

A single-arm prospective exploratory study.

Methods

Twenty-six eyes of 26 treatment naïve PCV patients were enrolled in this study. The primary outcome measures were the changes in best corrected visual acuity (BCVA) and the complete polyp regression rate. The secondary outcome measures included central retinal thickness assessed by optical coherence tomography.

Results

The patients showed significant improvement in BCVA by 0.14 logMAR units at 12 months and 0.11 logMAR units at 24 months from baseline (both p < 0.01). The mean central retinal thickness also significantly decreased at 12 months (p < 0.001) and at 24 months (p = 0.001). Complete regression of polypoidal lesions was achieved by 15 out of 20 eyes (75%) at 12 months and 11 out of 20 eyes (55%) at 24 months. The mean treatment number was 2.9 courses of IVA and 1.5 courses of vPDT and the mean retreatment free interval after initial therapy was 12.8 months during follow up of 24 months. The complete data from all predetermined examinations were observed in 17 out of 26 enrolled patients (65%) in this study.

Conclusion

In this study, combination therapy of IVA and vPDT yielded visual and anatomical improvements in treatment-naïve PCV patients over a 24-month follow-up period.

Keywords

Aflibercept Combination therapy Polypoidal choroidal vasculopathy PCV Photodynamic therapy 

Notes

Acknowledgements

This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant number JP16K11286 (S. Honda) and JSPS KAKENHI Grant number JP26861449 (W. Matsumiya)

Conflicts of interest

S. Nakai, None; W. Matsumiya, None; O. Keiko, None; A. Miki, None; M. Nakamura, None; S. Honda, None.

References

  1. 1.
    Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8.CrossRefGoogle Scholar
  2. 2.
    Uyama M, Matsubara T, Fukushima I, Matsunaga H, Iwashita K, Nagai Y, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol. 1999;117:1035–42.CrossRefGoogle Scholar
  3. 3.
    Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115:478–85.CrossRefGoogle Scholar
  4. 4.
    Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100–10.CrossRefGoogle Scholar
  5. 5.
    Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49:25–37.CrossRefGoogle Scholar
  6. 6.
    Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.CrossRefGoogle Scholar
  7. 7.
    Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015;122:1866–72.CrossRefGoogle Scholar
  8. 8.
    Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A, Iida T, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33:686–716.CrossRefGoogle Scholar
  9. 9.
    Koh AH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206–13.CrossRefGoogle Scholar
  10. 10.
    Saito M, Iida T, Kano M, Itagaki K. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251:2099–110.CrossRefGoogle Scholar
  11. 11.
    Yoshida Y, Kohno T, Yamamoto M, Yoneda T, Iwami H, Shiraki K. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2013;57:283–93.CrossRefGoogle Scholar
  12. 12.
    Kim M, Kim K, Kim DG, Yu S-Y, Kwak H-W. Two-year results of photodynamic therapy combined with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy. Ophthalmologica. 2011;226:205–13.CrossRefGoogle Scholar
  13. 13.
    Lee YA, Yang CH, Yang CM, Ho TC, Lin CP, Huang JS, et al. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up. Am J Ophthalmol. 2012;154:872–80.CrossRefGoogle Scholar
  14. 14.
    Hata M, Tsujikawa A, Miyake M, Yamashiro K, Ooto S, Oishi A, et al. Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2015;253:189–97.CrossRefGoogle Scholar
  15. 15.
    Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, et al. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:541–8.CrossRefGoogle Scholar
  16. 16.
    Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.CrossRefGoogle Scholar
  17. 17.
    Wang W, He M, Zhang X. Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies. PLoS One. 2014.  https://doi.org/10.1371/journal.pone.0110667.Google Scholar
  18. 18.
    Tang K, Si JK, Guo DD, Cui Y, Du YX, Pan XM, et al. Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis. Int J Ophthalmol. 2015;18:1056–66.Google Scholar
  19. 19.
    Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159:853–60.CrossRefGoogle Scholar
  20. 20.
    Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85.CrossRefGoogle Scholar
  21. 21.
    Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92:667–8.CrossRefGoogle Scholar
  22. 22.
    Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-Arakawa N, et al. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253:1471–7.CrossRefGoogle Scholar
  23. 23.
    Lee MY, Lee WK, Baek J, Kwon OW, Lee JH. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor. Am J Ophthalmol. 2013;156:343–8.CrossRefGoogle Scholar
  24. 24.
    Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:311–6.CrossRefGoogle Scholar
  25. 25.
    Takayama K, Kaneko H, Kataoka K, Hattori K, Ra E, Tsunekawa T, et al. Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: retrospective observation study. PLoS One. 2017.  https://doi.org/10.1371/journal.pone.0176100.Google Scholar
  26. 26.
    Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan Study. Retina. 2015;35:1569–76.CrossRefGoogle Scholar
  27. 27.
    Lee WK, Iida T, Ogura Y, Chen SJ, Wong TH, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study. A randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786–93.CrossRefGoogle Scholar
  28. 28.
    Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576–84.CrossRefGoogle Scholar
  29. 29.
    Oh IK, Huh K, Oh J. Risk factors for retinal hemorrhage after photodynamic therapy in age-related macular degeneration. Ophthalmologica. 2009;223:78–84.CrossRefGoogle Scholar
  30. 30.
    Lee MY, Lee WK, Baek J, Kwon OW, Lee JH. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor. Am J Ophthalmol. 2013;156:343–8.CrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2018

Authors and Affiliations

  1. 1.Division of Ophthalmology, Department of SurgeryKobe University Graduate School of MedicineKobeJapan
  2. 2.Department of Ophthalmology and Visual SciencesOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations